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Abstract 
Background and purpose: Essential tremor (ET) is a neurological disorder with unknown 
etiology. Its symptoms include cerebellar motor disturbances, cognitive and personality 
changes, hearing and olfactory deficits. Excitotoxic cerebellar climbing fibre hyperactivity 
may underlie essential tremor and has been emulated in rodents by systemic harmaline 
administration. Cannabinoid receptor agonists can cause motor disturbances although there 
are also anecdotal reports of therapeutic benefits of cannabis in motor disorders. We set out 
to establish the effects of cannabinoid type 1 receptor agonism and antagonism in an 
established rodent model of ET using a battery of accepted behaviour assays in order to 
determine risk and therapeutic potential of endocannabinoid system modulation in ET. 
 
Experimental Approach: The behavioural effects of systemic cannabinoid (CB) receptor 
agonist (0.1, 0.5 and 1mg kg-1 WIN55, 212-2) and antagonist (1mg kg-1 AM251 and 10mg kg-
1 rimonabant) treatment on harmaline-induced (30mg kg-1) tremor in rats was assessed 
using tremor scoring, open field, rotarod, grip and gait tests. 
 
Key Results: Overall, harmaline induced robust tremor that was typically worsened across 
the measured behavioural domains by CB type 1 (CB1) receptor agonism but ameliorated by 
cannabinoid type 1 receptor antagonism.  
 
Conclusions and Implications: These results provide the first evidence of effects of 
endocannabinoid system modulation on motor function in the harmaline model of essential 
tremor and suggest that CB1 receptor manipulation warrants clinical investigation as a 
therapeutic approach to protection against behavioural disturbances associated with 
essential tremor.  
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TARGETS   LIGANDS  AM251 
GPCRs CB1 Harmaline Rimonabant 
Ionotropic receptors GlyR WIN55,212-2  
 
 
Abbreviations: ET: essential tremor; PC: Purkinje cell; MS: multiple sclerosis;   
  
  
This article is protected by copyright. All rights reserved. 
Introduction:  
Simple essential tremor (ET) is a neurological disorder of unknown etiology (prevalence: 0.4-
3.9%), typically affecting upper limbs and, less commonly, the head, jaw, tongue, trunk and 
lower limbs. Although a syndrome of tremor in posture and movement, cerebellar motor 
disturbances, cognitive and personality changes, and hearing and olfactory deficits are also 
associated with ET (Deuschl et al., 2009). Interest in essential tremor remains high due to its 
relatively high prevalence, adverse effect upon quality of life (Schmouth et al., 2014) and 
apparently increasing prevalence in diseases like multiple sclerosis (MS) (~25%) (Fox et al., 
2004). ET treatment includes pharmacotherapy with beta adrenoceptor blockers, anticon-
vulsants, neuroleptics and antidepressants, although surgical treatments are required in the 
~50% of cases that are pharmacoresistant (Chopra et al., 2013) demonstrating a significant 
unmet clinical need (Koller et al., 1989).  
Excitotoxic climbing fibre hyperactivity has been suggested as one possible cause of 
ET and can be emulated in laboratory species by harmaline (i.p.), a beta carboline derivative 
of harmala alkaloids from Peganum harmala (Syrian Rue) seeds. Harmaline produces an 8–
16 Hz tremor in mice and rats and, in rats, is associated with Purkinje cell (PC) loss 
(Handforth, 2012).  
Recent studies have revealed a role for endocannabinoids in tremor disorders 
(Glass, 2001; Howard et al., 2013; Arjmand et al., 2015). Cannabinoid (CB) receptors and 
their endogenous ligands, the endocannabinoids, are abundant in brain areas that manage 
motor function where they play a neuromodulatory role (Rodriguez de Fonseca et al., 1998). 
Abundant cerebellar, CB type 1 (CB1) receptors expression, particularly on PC inputs from 
interneurons and excitatory climbing fibres arising from granule cells and PC synapses 
emphasises the importance of endocannbinoid signaling in the cerebellum where it 
modulates classical cerebellar neurotransmission via activity-induced inhibition of 
presynaptic neurotransmitter release through K+ channel-mediated inhibition of presynaptic 
Ca2+ influx (Daniel et al., 2004).  
  
This article is protected by copyright. All rights reserved. 
Although specific changes to cannabinergic signaling in motor diseases remains 
unclear and significant gaps in our understanding of cannabinergic influences on motor 
pathways remain, patients have claimed therapeutic benefits of medical cannabis in tremor-
associated diseases (Clifford, 1983). Reduced tremor and spasticity in animal models of MS 
has been reported following treatment with 9-tetrahydrocannabinol, a psychoactive plant 
cannabinoid (Koch et al., 2007; Baker et al., 2000) and numerous but unsubstantiated 
patient claims for benefits of cannabis use in ET have been made (Tudge et al., 2015). 
Interestingly, an extensive literature shows dose-dependent effects of the CB receptor partial 
agonist, 9-tetrahydrocannabinol (THC) in this regard (Frederickson et al., 1976; Kujtan et 
al., 1983; Stanford et al., 1998; Freedland et al., 2002). Most notably, a systematic review 
revealed that Δ9-THC was probably ineffective for easing MS-related tremors (Koppel et al., 
2014) while, conversely, sustained use of Δ9-THC-rich extracts reduced tremor and 
spasticity in MS (Buccellato et al., 2011). Thus, a confusing literature surrounds cannabinoid 
effects upon tremor in MS and, to date, no studies have investigated cannabinoid effects in 
ET, a discrete disorder. Therefore, here we report effects of a CB receptor agonist and CB1 
receptor antagonists on harmaline-induced tremor in rats, using behavioural measures to 
determine whether endocannabinoid modulation represents a plausible therapeutic strategy 
for the treatment of ET, in addition to assessing potential risks associated with therapeutic or 
recreational use of cannabinoid preparations by ET patients. 
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Methods: 
Male Wistar Kyoto rats (40–60g (P24-28); Kerman Neuroscience Research Center) 
were used in accordance with National Institutes of Health guidance and approved the 
Kerman University of Medical Sciences. Information regarding the use of animals reported 
herein complies with ARRIVE guidelines (McGrath & Lilley, 2015). Animals were group 
housed (2-3 animals per cage) in conventional laboratory rodent cages (Razirad Co., Iran) of 
dimensions 26.5 (W) x 15 (H) x 42 (L) cm and maintained on a 12h light–dark cycle at a 
23±2°C with access to food and water ad libitum. Experiments were conducted during the 
light phase (08:00-16:00h).  
Three experiments (see Experimental design below) were undertaken, each of 
which employed five behavioural tasks: tremor scoring, open field test, rotarod test, grip 
strength test and gait analysis test (Vaziri et al., 2015). Tests were administered 
sequentially. Pilot studies (n=16) revealed that 30mg kg-1 harmaline induced stable tremor in 
this population for the duration of the testing period (2.5-3hrs). Previous studies have 
revealed that harmaline produces tremor at doses of 9-50mg kg-1 in laboratory rodent 




Tremor was rated by two observers blinded to treatment. Intra- and inter-observer reliability 
were assessed via kappa coefficient (acceptance criterion: >80%). Tremor data were 
acquired during the open field test and quantitatively scored as follows: 0: No tremor, 1: 
occasional tremor affecting only the head and neck, 2: intermittent (occasional tremor 
affecting all body parts), 3: persistent (persistent tremor affecting all body parts and tail), 4: 
severe (persistent tremor rendering the animal unable to stand and/or walk) (Al-Deeb et al., 
2002). Number of rearing events (standing on hind paws with a body-floor angle >45° 
(Lamprea et al., 2008) (a measure of vertical and explorative activity related to locomotor 
behaviour) and number of grooming events (coordinated, patterned, obsessive motor action 
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(Komorowska et al., 2004; Kalueff et al., 2007) of front paws or mouth on the fur) per session 
were also recorded.  
 
Open-field test assessing locomotor behaviour 
A Plexiglas arena (90 [W] × 90 [L] × 30 [H] cm) was used. Each animal was placed in the 
center of the arena and horizontal activity recorded for 5 minutes with subsequent offline 
analysis (Ethovision 7.1, Noldus Information Technology, Netherland) that assessed total 
distance moved, duration of mobility and speed. The chamber was cleaned with 70% 
ethanol and dried between sessions (Vaziri et al., 2015).  
 
Rotarod test 
Motor and balance performance were evaluated by accelerating rotarod device (Hugo 
Sachs, Germany). Prior to placing an animal on the apparatus, rod rotation was set to 10 
rpm. At test start, the animal was placed on the rod which was linearly accelerated at 10 
rpm/minute to a maximum of 60 rpm. Each animal undertook three trials with a 30 min inter-
trial rest interval. The duration for which each animal remained in the apparatus was 
recorded and the mean for all trials per animal calculated (Vaziri et al., 2015). 
 
Wire grip test 
The wire grip test assesses muscle strength and balance (Marks et al., 2009). Each animal 
was suspended by both forepaws from a horizontal steel wire [80cm long, 7mm diameter] 
suspended 45cm from the ground. Each animal was held in a vertical position when its front 
paws were placed in contact with the wire. When the animal grasped the wire, it was 
released and latency to fall recorded with a stopwatch. Each animal undertook three trials 
with a 5 minute inter-trial rest interval. 
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Gait analysis test 
The gait analysis test assesses animal walking patterns and gait kinematics. The hind paws 
of each animal were marked with a non-toxic ink and the animal allowed to traverse a clear 
Plexiglas tunnel (100 cm [L]×10 cm [H]×10 cm [W]) lined with white absorbent paper 
(100 cm × 10 cm) and ending in a darkened cage. The resulting tracks provide the spatial 
relationship of consecutive footfalls from which animal stride length and width were 
measured. Animals were habituated to the runway for 3 training runs before testing. Hind 
paw stride lengths were measured by distance (cm) between the respective paw prints to the 
successive ipsilateral prints to assess uni- or bi-lateral effects of treatment upon gait. Hind 
paw stride widths were measured by distance between the centers of the respective paw 
prints to the corresponding contralateral stride length measurements at a right angle. 
Footprints at the beginning and end of each run were not considered in the analysis (Wecker 
et al., 2013). 
 
Drugs 
The non-selective CB receptor agonist, WIN55, 212-2 (Sigma, USA), and CB1 receptor 
selective antagonists, AM251 (Sigma) and rimonabant (Cayman, USA) were first dissolved 
in dimethylsulfoxide before further dilution in dH2O (DMSO; maximum DMSO concentration: 
1%v/v.  Harmaline hydrochloride dihydrate (Sigma) was dissolved in dH2O. Drugs were 
administered i.p. to a maximum total injection volume of 1 ml. 
 
Experimental design 
The present study comprised three discrete experiments. Experiment 1 assessed the 
effects of harmaline in the behavioural tests described. Here, two groups of animals were 
employed, one of which received harmaline (30 mg kg-1; i.p.) and the other harmaline vehicle 
(dH2O; i.p.), each 15 minutes before behavioural testing began. Experiment 2 assessed the 
effect of CB receptor agonism upon harmaline-induced symptoms. Here, four groups of 
animals were used where one received WIN55, 212-2 vehicle (i.p.; administered 30 minutes 
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before harmaline) plus harmaline (30 mg kg-1; i.p.; 15 minutes before behavioural testing) 
and three received WIN55, 212-2 at doses of 0.1, 0.5 & 1 mg kg-1 (i.p.; administered 30 
minutes before harmaline) plus harmaline (30mg kg-1; i.p.; 15 minutes before behavioral 
testing). Finally, Experiment 3 examined the effects of CB1 receptor antagonism upon 
harmaline-induced symptoms. Here, three groups of animals were used where one received 
AM251/rimonabant vehicle (i.p.; administered 30 minutes before harmaline) plus harmaline 
(30mg kg-1; i.p.; 15 minutes before behavioral testing) and two received either AM251 (1mg 
kg-1; i.p.; administered 30 minutes before harmaline) or rimonabant (10mg kg-1; i.p.; 
administered 30 minutes before harmaline) plus harmaline (30mg kg-1; i.p.; 15 minutes 
before behavioral testing).  
In vitro, AM251 exhibits greater affinity for CB1 receptors (3-10 fold; dependent on 
assay) and exerts greater inhibition of agonist effects at CB1 receptors (6-10 fold difference 
in IC50; dependent on assay and agonist) (Pertwee (2005). Therefore, AM251 and 
rimonabant were employed at doses of 1 and 10 mg kg-1 respectively. CB receptor agonists 
and antagonists employed in the present study were also examined for effects in the tasks 
described when administered in the absence of harmaline (doses as stated above; i.p.; 45 
minutes before testing began; See Supplemental Results; Figures S3A & S4A vs other 
supplemental Figures S1-S4). Briefly, when administered in the absence of harmaline, only 
rimonabant treatment affected any measure where a decrease in rearing events and time on 
rotarod were observed. 
 
Statistical analysis 
On entry into the study, 192 animals were randomized, using an online tool 
(http://graphpad.com/quickcalcs/randomize1/; seeded using the time of day) into 16 groups 
of 12 animals as described. Where animals failed to complete a task and provide valid data, 
no value was included for analysis. Reasons for task failure included: failure to habituate to 
handling, failure to habituate to equipment, technical (e.g. equipment) failure or data 
provided not amenable to robust analysis (e.g. indistinguishable footprints in the gait task). 
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The number of animals per group per assay that contributed data for quantitative analysis 
are shown in parentheses in each figure. Group size was determined by sample size 
calculation to provide statistical power of ≥80% to detect effect sizes consistent with relevant 
comparators previously described for this animal model (Handforth, 2012) at the 5% level of 
significance with the intention to establish differences between control and study drug 
groups.  
Experimental data were collected by researchers blinded to drug treatment and 
analysed by an independent researcher blinded to group identity. Data were unblinded prior 
to pairwise statistical comparisons (see below) in order to allow specification of the 
comparator control group. SPSS (IBM, USA), Origin (OriginLab Co., MA, USA) and 
GraphPad Prism 6 (GraphPad Software, USA) were used for statistical analysis of data and 
figure production. Prior to the conduct of comparative statistics, the presence or not of outlier 
data points pooled by task was assessed using the ROUT method as implemented in 
GraphPad Prism 6 (Motulsky & Brown, 2006). These data were excluded from the statistical 
analysis and comprised 6/1648 (~0.3%) data points across all groups and all assays. Data 
were then assessed for normality using a Kolmogorov-Smirnov test. Results found to be 
normally distributed (p>0.05 in K-S test) were expressed as mean±SEM and analyzed using 
either a paired Student’s t-test or a one-way ANOVA test. Where a main effect was seen in 
ANOVA tests, pairwise comparisons between control and each drug treated group were then 
made using Tukey’s post-hoc tests. Results that were not normally distributed (p<0.05 in K-S 
test) were expressed as median and interquartile range (expressed as median (interquartile 
range)) and analysed using either a Mann Whitney test or a Kruskal-Wallis test. Where a 
main effect was seen in Kruskal-Wallis tests, pairwise comparisons between control and 
each drug treated group were then made using Dunn's multiple comparisons test. In each 
case, p<0.05 was considered statistically significant.   
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Results 
Experiment 1 assessed the effects of harmaline versus a single, dH2O-treated control 
group. Harmaline reliably induced a significant and persistent tremor that affected all body 
parts (median tremor score: harmaline: 3 (0.25); control: 0 (0); p<0.05; Fig. 1A) and also 
significantly reduced rearing (median rearing events: harmaline: 0 (1); control: 28 (10); 
p<0.05; Fig. 1B) and grooming events (median grooming events: harmaline: 1(1); control: 
2.5 (3.75); p<0.05; Fig. 1C). In the open field test, harmaline significantly decreased total 
distance moved (median distance moved: harmaline: 1097 (373) cm; control: 2734 (297) cm; 
p<0.05; Fig 1D) while mean mobility duration (harmaline: 2.0±0.4 s; control: 4.9±0.7 s; 
p<0.05; Fig. 1E) and median speed (harmaline: 3.7 (1.4) cm s-1; control: 9.1 (2.2) cm s-1; 
p<0.05; Fig. 1F) were also significantly decreased by treatment. In the rotarod test, median 
time on the apparatus was significantly decreased by harmaline treatment (harmaline: 33.0 
(4.9) s; control: 300.0 (79.1) s; p<0.05; Fig. 2A) and, similarly, treatment significantly 
decreased median gripping time in the grip strength test (harmaline: 15.8 (4.0) s; control: 
177.5 (32.1) s; p<0.05; Fig 2B). When animal gait was assessed, harmaline significantly 
increased mean gait width (harmaline: 5.9±0.2 cm; control: 2.2±0.0 cm; p<0.05; Fig. 2C) and 
reduced mean right (harmaline: 6.9 ± 0.2 cm; control: 8.4±0.2 cm; p<0.05; Fig 2D) and left 
(harmaline: 6.4±0.2 cm; control: 8.2±0.3 cm; p<0.05; Fig 2E) stride length. These results 
demonstrate that 30mg kg-1 harmaline treatment reliably and reproducibly induces severe 
tremor associated with significant functional deficits that can be detected and assessed 
using the tasks employed. 
 
Experiment 2 assessed the effect of CB receptor agonism upon the harmaline-induced 
symptoms described in Experiment 1. The CB receptor agonist, WIN55, 212-2 (0.1, 0.5 & 
1mg kg-1) or vehicle was administered 30 minutes before harmaline (30mg kg-1) and effects 
assessed behaviourally as previously described. Here, an overall effect of treatment upon 
median harmaline-induced tremor (H(3)=12.1, p<0.05; Fig 3A), median rearing events 
(H(3)=13.47, p<0.05; Fig 3B) and median grooming events was seen (H(3)=18.01, p<0.05; 
  
This article is protected by copyright. All rights reserved. 
Fig 3C) although subsequent pairwise comparisons only revealed significant effects of 
higher WIN55, 212-2 doses upon grooming events (WIN55, 212-2 0.5mg kg-1: p<0.05; 
WIN55, 212-2 1mg kg-1: p<0.05; vs harmaline plus WIN55, 212-2 vehicle treated controls; 
Fig. 3C).  
In the open field test, no overall effects of treatment upon mean total distance moved 
(F3, 41=2.270, p>0.05; Fig 3D) or median mobility duration (H(3)=4.509, p>0.05; Fig 3E) were 
seen although mean movement speed (F3, 37=4.688, p<0.05; Fig 3F) was affected where 
post hoc tests revealed that WIN55, 212-2 1mg kg-1 significantly reduced movement speed 
(p<0.05 vs harmaline plus WIN55, 212-2 vehicle treated controls). In the rotarod test, a main 
effect of treatment upon median time on the rotarod apparatus (H(3)=14.21, p<0.05) was 
seen where WIN55, 212-2 caused a dose dependent exacerbation of harmaline effects on 
this measure (WIN55, 212-2 0.5mg kg-1: p<0.05; WIN55, 212-2 1mg kg-1: p<0.01; each vs 
harmaline plus WIN55, 212-2 vehicle treated controls; Fig. 4A). Furthermore, treatment 
significantly affected median grip strength (H(3)=20.28, p<0.05) although post hoc 
comparisons revealed that only WIN55, 212-2 0.5mg kg-1 significantly reduced gripping time 
(p<0.001 vs harmaline plus WIN55, 212-2 vehicle treated controls; Fig. 9B). Finally, when 
animal gait was assessed, significant effects of treatment upon median gait width 
(H(3)=13.32, p<0.05; Fig. 4C) and median stride length (right stride: H(3)=17.35, p<0.05; left 
stride: H(3)=9.703, p<0.05; Figs 4D&E) were seen. Post hoc comparisons with harmaline 
plus WIN55, 212-2 vehicle treated controls tests revealed that WIN 55,212-2 0.1mg kg-1 
decreased the harmaline-induced increase in gait width (p<0.05) although WIN 55,212-2 
1mg kg-1 exacerbated the harmaline-induced decrease in right (p<0.05), but not left, stride 
length. 
 
Experiment 3 assessed the effects of cannabinoid type 1 receptor antagonism upon 
harmaline-induced symptoms by examining the effects of the CB1 receptor selective 
antagonists AM251 (1mg kg-1) and rimonabant (10mg kg-1) when administered 30 minutes 
before harmaline (30mg kg-1) in our battery of behavioural tasks. A significant effect of drug 
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treatment (H(2)=17.02, p<0.05) on median tremor score was seen and post hoc tests 
revealed that AM251 (p<0.05) and rimonabant (P<0.05; Fig. 5A) significantly reduced tremor 
scores when compared to harmaline plus vehicle controls. When rearing events were 
assessed, a main effect of treatment was detected (H(2)=12.86, p<0.05) and revealed that 
rimonabant significantly increased rearing events when compared to harmaline plus vehicle 
(p<0.05, Fig. 5B). A significant effect of treatment upon grooming events was also seen 
(H(2)=19.88, p<0.05) where both antagonists produced significant increases when 
compared to harmaline plus vehicle (AM251: p<0.05; rimonabant: p<0.05; Fig. 5C). In the 
open field test, significant effects of treatment was seen on the median total distance moved 
(H(2)=17.51, p<0.05), mean mobility duration (F2, 27=10.84, p<0.05) and mean movement 
speed (F2, 27=3.792, p<0.05). Here, when comparisons were made vs the harmaline plus 
vehicle group, post hoc tests revealed that both AM251 and rimonabant significantly 
increased total distance moved (AM251: p<0.05; rimonabant: p<0.05; Fig. 5D) and mobility 
duration (AM251: p<0.05; rimonabant: p<0.05; Fig. 5E) but only rimonabant significantly 
increased movement speed (p<0.05; Fig 5F).  
 
In the rotarod test, a main effect of treatment upon mean time on the apparatus was seen 
(F2, 23=47.21, p<0.05) that revealed CB1 receptor antagonist treatment to significantly 
increase times on the rod when compared to harmaline plus vehicle controls (AM251: 
p<0.01; rimonabant: p<0.05; Fig. 6A). In the grip strength test, a similar effect was seen 
where the main effect of treatment (F2, 24=24.04, p<0.05) arose from significant effects of CB1 
receptor antagonism to increase mean grip time (AM251: p<0.05; rimonabant: p<0.05; Fig. 
6B). Finally, in our analysis of gait, a significant effect of treatment was seen upon median 
stride width (H(2)=14.71, p<0.05; Fig. 6C) but not mean stride length (right: F2, 25=1.559, 
p>0.05& left: F2, 25=2.685, p>0.05; Figs 6D&E) where post hoc tests revealed that CB1 
receptor antagonism reduced stride width (AM251: p<0.05; rimonabant: p<0.05 when 
compared to harmaline plus vehicle controls. 
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Discussion 
Essential tremor (ET) is the most common movement disorder (Louis et al., 1998), has 
unmet clinical need (~50% pharmacoresistance) and is most frequently cerebellar in origin. 
The endocannabinoid system plays an important role in cerebellar function and CB1 receptor 
expression is at its most abundant in mammalian cerebellum (Miller et al., 2011). However, 
while behavioural effects of CB1 receptor agonism in healthy laboratory species are well 
established (Little et al., 1988), CB1 receptor modulation in ET has never been examined. 
Such a study is important and timely since the endocannabinoid system may represent an 
unexploited target for ET pharmacotherapy. Moreover, recreational cannabis use and 
cannabinoid medicine use is increasing, raising exposure risk in ET patients. Finally, 
recreational abuse of synthetic cannabinoids (typically CB1 receptor agonists) is also 
increasing, presenting additional risks within the ET patient population (Fox et al., 2004; 
Gilman et al., 2014; Tudge et al., 2015). We therefore assessed the effects of CB receptor 
agonism and CB1 antagonism in a murine ET model using five conventional behavioural 
assessments. 
 In our first experiment, and consistent with the literature, harmaline reliably induced 
tremor (Martin et al., 2005) which manifested as notable performance deficits in all of the 
behavioral tasks employed. Thus, significant reductions in rearing and grooming events, 
distance moved by animals in the open field test, mobility duration, movement speed, time 
on rotarod, grip strength, bilateral gait width and stride length. Harmaline produces tremor, 
the severity of which is reliably dose-dependent and species-specific (Miwa et al., 2006).  
Notably, studies seeking to detect the effects of agents that are hypothesised to potentiate 
ET (e.g. caffeine (Al-Deeb et al., 2002)) most commonly employ a lower dose of harmaline 
(e.g. 10 mg kg-1) while conversely, those exploring the potential therapeutic utility of novel 
agents to treat ET symptoms will most often employ higher harmaline doses (e.g. 30 mg kg-
1) (Shourmasti et al., 2014). Here, since a severe tremor state was required, upon which only 
potent ameliorating or exacerbating pharmacological effects of the cannabinodis studied 
would be revealed, a harmaline dose of 30 mg kg-1 was employed. The primary cause of 
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harmaline-induced tremor is via alteration of synchronous activation of climbing fibres from 
the inferior olive projecting to cerebellar PC (Kolasiewicz et al., 2009), most likely via 
repetitive discharge generation in inferior olivary nucleus neurons through potentiation of 
CaV3.1 calcium channels responsible for intrinsic oscillatory activity in this neuronal 
population (Miwa et al., 2011).  
One of the most reported effects of cannabis in a survey of MS patients was tremor 
relief (Koch et al., 2007). However, other studies have reported that cannabis does not 
improve MS-associated tremor (Fox et al., 2004; Koppel et al., 2014) and static ataxia can 
be reliably induced by CB1 receptor agonism in dogs and mice (Dewey et al., 1972). In our 
second experiment, we examined the consequences of CB receptor activation upon 
harmaline-induced behavioural deficits in rat. Here, CB receptor agonism largely 
exacerbated harmaline-induced symptoms as demonstrated by reduced grooming events, 
movement speed and time spent on the rotarod, consistent with CB1 receptor agonist effects 
in healthy animals (Little et al., 1988). While these effects occurred only at higher doses of 
WIN55,212-2 and suggested a possible dose-dependent effect, CB receptor agonism also 
exerted conflicting and apparently dose independent effects upon features of gait. Here, only 
the lowest dose of WIN55,212-2 partially reverse harmaline-induced changes in stride width 
yet the highest dose exacerbated right, but not left stride length. Similarly, only the middle 
dose of WIN55,212-2 exacerbated the harmaline-induced decrease in grip strength which 
was unaffected by either the lowest or highest doses.  
WIN55,212-2 is an agonist that acts at both CB1 and CB2 receptors. While the 
presence and functional relevance of central CB2 receptors remains controversial (Xi et al., 
2011, Morgan et al., 2009), the potential for some of the effects of WIN55,212-2 reported 
here to have been mediated, wholly or in part, via CB2 receptor activation cannot be ruled 
out. Overall, CB receptor agonism typically worsened harmaline-induced symptoms as 
assessed using the behavioural measures employed. While some conflicting results were 
found in more nuanced tests of motor function (e.g. gait), they did not appear to be dose 
  
This article is protected by copyright. All rights reserved. 
dependent and no indication of potential therapeutic benefit was seen in tests which 
assessed fundamental features of the model (e.g. tremor).     
Our previous in vitro studies have suggested that CB1 receptor antagonism may be 
beneficial in movement disorders by reducing CB1 receptor-mediated inhibition of GABA 
release (Ma et al., 2008). In the present study, we have shown that CB1 receptor antagonism 
can ameliorate severe ET symptoms and represents the first behavioural evidence of such 
clinical potential in an established and relevant animal model. Importantly, the two CB1 
receptor antagonists tested both significantly decreased harmaline-induced tremor score, 
showing beneficial effects on the primary behavioural deficit exhibited in this model. 
Moreover, while not reaching magnitudes comparable with control animal behaviours, both 
AM251 and rimonabant increased grooming events when compared to animals only treated 
with harmaline, while rimonabant alone increased rearing events, largely consistent with 
previous reports (Zavatti M1, 2011). CB1 receptor antagonism also exerted beneficial effects 
in the open field test where both antagonists tested ameliorated harmaline-induced 
behavioural deficits in all measured domains (with the exception of AM251 in movement 
speed). Similarly, both antagonists exerted beneficial effects upon harmaline-induced 
adverse effects in the rotaroad and grip strength tasks in addition to ameliorating harmaline 
effects upon stride width but not stride length. Thus, blockade of endocannabinergic tone 
exerts intrinsic therapeutic benefit in this rodent model of severe ET. Harmaline treatment 
evokes rhythmic burst-firing activity in the medial and dorsal accessory inferior olivary nuclei 
that is propagated via climbing fibres to Purkinje cells, before further transmission to deep 
cerebellar nuclei, brainstem and spinal cord, consistent with our previous observation (Ma et 
al., 2008) that CB1 receptor antagonism inhibits Purkinje cell firing via blockade of 
endocannabinergic inhibition of GABA release although the involvement of other, additional, 
endocannabinoid-mediated processes cannot yet be eliminated.  
While a reversal by cannabinoid type 1 receptor antagonism of harmaline effects 
upon simple motor functions or their exacerbation by CB1 receptor agonists most likely arise 
predominantly from central CB1 receptor-mediated effects, some CB1 receptor antagonists 
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exert off target effects. Therefore, and particularly with regard to results where a clear dose-
related response was not evident, further investigation is warranted to determine potential 
interplay between such signaling systems. In vitro, rimonabant and AM251 can allosterically 
potentiate GABAA receptors at nanomolar concentrations although their site of action is 
distinct from other allosteric modulators of this receptor (Baur et al., 2012; Giovanni 
Battistella, 2014 ). Moreover, GlyRs are involved in a number of movement disorders (Yang 
et al., 2008) and exhibit a distinct pharmacological profiles for several cannabinoid 
compounds and cannabinoid receptor ligands and so establish GlyRs as novel targets for 
endogenous and exogenous cannabinoids (Yang et al., 2008). 
Similar to the cerebellum and ET, CB1 receptor expression is also abundant in the 
cerebral ganglia (Pacher et al., 2009) and has been studied in a primate model of 
dyskinesia. Here, while rimonabant reduced dyskinetic symptoms (van der Stelt et al., 2005), 
another CB1 receptor antagonist, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-
methylpyrazolo[1,5-a]-[1,3,5] triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide 
benzenesulfonate failed to affect dyskinetic symptoms (Cao et al., 2007). Moreover, the CB 
receptor partial agonist, nabilone, also alleviated symptoms in the same model (Fox et al., 
2002) and in a small clinical pilot (Sieradzan et al., 2001) but these results were not 
replicated in a randomized-controlled clinical trial (Carroll et al., 2004). Thus, as found in the 
present study with respect to CB1 receptor modulation of ET symptoms, other dyskinesias 
appear either improved or unaffected by CB1 receptor antagonism but paradoxically 
alleviated and exacerbated by CB receptor agonism. This contradiction, exemplified by our 
own results and those describing therapeutic benefits of CB1 receptor agonism in animal 
models of chronic tremor (Koch et al., 2007; Baker et al., 2000) may suggest that overall 
effects are determined by the aetiology of the disorder modelled. Thus, in a chronic 
encephalomyelitis modelling multiple sclerosis (Baker et al., 2000) where widespread 
demyelination and axon loss occurs, CB receptor agonism can be of use while in acute 
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tremor arising from cerebellar hyperexcitability (e.g. harmaline treatment) to model idiopathic 
ET, CB1 receptor antagonism is beneficial.  
In conclusion, our results demonstrate that acute CB1 receptor antagonism improves 
severe ET symptoms and so demonstrates their therapeutic potential for ET. Rimonabant 
was previously licensed for weight loss although was withdrawn in 2008 following reports of 
psychiatric side effects in a trial population where higher doses were employed (Moreira et 
al., 2009). However, adverse reactions of this nature do not necessarily preclude the use of 
a treatment (e.g. suicidal ideation associated with SSRIs) (Ghaziuddin et al., 2014) and so 
should not hinder drug development if warranted by unmet clinical. Moreover, rimonabant 
has since been shown to act as an inverse agonist at CB1 receptors (Landsman et al., 1997) 
and so making investigation neutral CB1 receptor antagonists (e.g. ∆
9-
tetrahydrocannabidavarin (Tudge et al., 2015)) in ET compelling since it is already known to 
modulate PC firing in vitro (Ma et al., 2008).   
Our study reinforces the pivotal role of the endocannabinoid system in motor function 
and highlights its therapeutic potential in the treatment of ET symptoms. Our novel findings 
justify further study of the basic neuronal circuits that subserve CB1 receptor antagonist 
therapies for ET alongside further in vivo studies to elucidate mechanisms of CB1 receptor 
antagonist effects on harmaline symptoms (e.g. central microdialysis). Moreover, while 
harmaline-induced tremor is a valuable first line model used to inform prioritisation of 
candidate ET treatments for subsequent investigation it is necessarily limited as a result of 
its acute nature.  Harmaline-induced tremor is predictive of clinical efficacy in ET in ~50% of 
cases (Handforth, 2012) and so the findings presented here strongly support further 
preclinical study of repeated CB1 receptor antagonist treatment in animal models disease 
(c.f. models of acute symptoms as used here) and subsequent clinical development. 
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Figure 1. Experiment 1: The effect of harmaline (30 mg kg-1; i.p.) upon (A) tremor score, (B) 
rearing events per session and (C) grooming events per session. Results from the same 
treatment in the open field test are shown as (D) total distance moved (cm), (E) mobility 
duration (s) and (F) movement speed (cm s-1). Data describing mobility duration exhibited a 
normal distribution and are represented as mean±SEM. Data describing tremor score, 
rearing events, grooming events, total distance moved and movement speed were not 
normally distributed and are represented as medians with interquartile ranges as a box and 
maxima/minima as whiskers. *= p<0.05 where all comparisons were made with the vehicle 
(dH2O; i.p) treated control group. Numbers in parentheses indicate group sizes. No data 
points were excluded as outliers in the presented analyses. 
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Figure 2. Experiment 1: The effect of harmaline (30 mg kg-1; i.p.) upon (A) time spent on 
rotarod apparatus and (B) gripping time in the wire grip test. Results from the same 
treatment in the gait analysis test are shown as (C) hind paw stride width (cm), (D) right hind 
paw stride length (cm) and (F) left hind paw stride length (cm). Data describing measures 
from the gait analysis exhibited a normal distribution and are represented as mean±SEM. 
Data describing time on the rotarod apparatus and gripping time in the wire grip test were 
not normally distributed and are represented as medians with interquartile ranges as a box 
and maxima/minima as whiskers. *= p<0.05 where all comparisons were made with the 
vehicle (dH2O; i.p) treated control group. Numbers in parentheses indicate group sizes. No 
data points were excluded as outliers in the presented analyses. 
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Figure 3. Experiment 2: The effect of CB receptor agonist (WIN55,212-2 0.1, 0.5 & 1 mg kg-
1; i.p.) treatment upon harmaline (30 mg kg-1; i.p.) induced symptoms. (A) tremor score, (B) 
rearing events per session and (C) grooming events per session. Results from the same 
treatment in the open field test are shown as (D) total distance moved (cm), (E) mobility 
duration (s) and (F) movement speed (cm s-1). Data describing total distance moved and 
movement speed exhibited a normal distribution and are represented as mean±SEM. Data 
describing tremor score, rearing events, grooming events and mobility duration were not 
normally distributed and are represented as medians with interquartile ranges as a box and 
maxima/minima as whiskers. *= p<0.05 where all comparisons were made with the 
harmaline only group. Numbers in parentheses indicate group sizes. No data points were 
excluded as outliers in the presented analyses. 
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Figure 4. Experiment 2: The effect of CB receptor agonist (WIN55-212,2 0.1, 0.5 & 1 mg kg-
1; i.p.) treatment upon harmaline (30 mg kg-1; i.p.) induced symptoms. (A) time spent on 
rotarod apparatus and (B) gripping time in the wire grip test. Results from the same 
treatment in the gait analysis test are shown as (C) hind paw stride width (cm), (D) right hind 
paw stride length (cm) and (F) left hind paw stride length (cm). Data for all measures in this 
experiment were not normally distributed and are represented as medians with interquartile 
ranges as a box and maxima/minima as whiskers. *= p<0.05 where all comparisons were 
made with harmaline only group. Numbers in parentheses indicate group sizes. 3/199 data 
points were detected as outliers and excluded from the presented analyses. 
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Figure 5. Experiment 3: The effect of CB1 antagonist (AM251 1 mg kg-1 and rimonabant 10 
mg kg-1; both i.p.) treatment upon harmaline (30 mg/kg; i.p.) induced symptoms. (A) tremor 
score, (B) rearing events per session and (C) grooming events per session. Results from the 
same treatment in the open field test are shown as (D) total distance moved (cm), (E) 
mobility duration (s) and (F) movement speed (cm s-1). Data describing mobility duration and 
movement speed exhibited a normal distribution and are represented as mean±SEM. Data 
describing tremor score, rearing events, grooming events and total distance moved were not 
normally distributed and are represented as medians with interquartile ranges as a box and 
maxima/minima as whiskers. *= p<0.05 where all comparisons were made with the 
harmaline only treated group. Numbers in parentheses indicate group sizes. 3/172 data 
points were detected as outliers and excluded from the presented analyses. 
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Figure 6. Experiment 3: The effect of CB1 antagonist (AM251 1 mg kg-1 and rimonabant 10 
mg kg-1; both i.p.) treatment upon harmaline (30 mg kg-1; i.p.) induced symptoms. (A) time 
spent on rotarod apparatus and (B) gripping time in the wire grip test. Results from the same 
treatment in the gait analysis test are shown as (C) hind paw stride width (cm), (D) right hind 
paw stride length (cm) and (F) left hind paw stride length (cm). Data for time on rotarod 
apparatus, gripping time in the wire grip test, and right and left hind paw stride lengths were 
normally distributed and are represented as mean±SEM. Hind paw stride width data were 
not normally distributed and are represented as medians with interquartile ranges as a box 
and maxima/minima as whiskers. *= p<0.05 where all comparisons were made with 
harmaline only group. Numbers in parentheses indicate group sizes. No data points were 
excluded as outliers in the presented analyses. 
 
